CF
CFRXQ.US ContraFect Corporation
- Market cap
- USD 107.00
- P/E
- -
- P/B
- 0.44x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is CFRXQ.US undervalued?
Graham numberThe Graham number of ContraFect Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ContraFect Corporation fundamental analysis
No fundamental analysis for ContraFect Corporation yet.
ContraFect Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical t…
Full company profileContraFect Corporation financial statements
ContraFect Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -451K | -187K | -151K | -169K | -168K | -148K | -154K | - |
| Operating Income | -33.5M | -26.6M | -32.3M | -27.9M | -34.2M | -47.3M | -56.9M | -37.7M |
| EBITDA | -28.1M | -15.3M | -37.5M | -12.6M | -28.0M | -20.1M | -65.0M | - |
| Net Income | -28.5M | -15.5M | -37.7M | -12.8M | -28.2M | -20.3M | -65.2M | -35.8M |
| EPS | -681 | -223 | -396 | -124 | -99 | -44 | -125 | - |
| Balance Sheet | ||||||||
| Total Assets | 37.6M | 50.2M | 32.9M | 35.0M | 51.1M | 66.8M | 20.7M | - |
| Total Liabilities | 18.1M | 19.0M | 27.3M | 19.5M | 38.5M | 17.4M | 32.5M | - |
| Shareholders' Equity | 19.5M | 31.2M | 5.54M | 15.5M | 12.6M | 49.4M | -11.9M | - |
| Cash & Short-term Investments | 35.2M | 46.9M | 30.5M | 24.2M | 42.5M | 54.3M | 13.7M | - |
| Total Debt | - | - | - | 3.90M | 3.60M | 3.27M | 2.88M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -29.3M | -24.5M | -26.3M | -27.4M | -33.2M | -41.1M | -46.0M | -35.6M |
| Capital Expenditure | 113K | 0.00 | 133K | 20.0K | 5.00 | 0.00 | 62.0K | 63.0K |
| Free Cash Flow | -29.4M | -24.5M | -26.4M | -27.4M | -33.2M | -41.1M | -46.0M | -35.6M |
| Ratios | ||||||||
| ROE | -146.3% | -49.7% | -680.0% | -82.3% | -223.1% | -41.1% | - | - |
| ROA | -75.9% | -30.9% | -114.6% | -36.5% | -55.1% | -30.4% | -315.1% | - |
| Debt to Equity | - | - | - | 0.25x | 0.29x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
ContraFect Corporation dividends
ContraFect Corporation has not paid dividends in the last 8 fiscal years.
Last stock split: 1:80 on Feb 15, 2023.
Who owns ContraFect Corporation
- Insiders 0.00%
- Institutions 11.10%
- Public & others 88.90%
- Shares outstanding 10.7M
- Free float 10.7M
ContraFect Corporation company profile
- Company name
- ContraFect Corporation
- Ticker
- CFRXQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- September
- Address
- 28 Wells Avenue, Yonkers, NY, United States, 10701
- Phone
- 914 207 2300
- Website
- contrafect.com
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
ContraFect Corporation management
5- Mr. Michael Messinger CPACEO, President, CFO & Principal Accounting Officer · born 1975
- Ms. Natalie Bogdanos J.D.General Counsel, Corporate Secretary & Data Protection Officer · born 1969
- Mr. Matthew Salamone P.H.R., SPHRVice President of Human Resources
- Dr. Gary WoodnuttSenior Vice President of Translational Sciences & Preclinical Development · born 1957
- Dr. William Garrett Nichols M.D., M.S.Interim Chief Medical Officer · born 1969